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Modiﬁcation/chlorination of high-density lipoprotein (HDL) by hypochlorous acid (HOCl), formed by the
myeloperoxidase–H2O2–chloride system of activated phagocytes, converts an anti-atherogenic lipopro-
tein into a pro-inﬂammatory lipoprotein particle. Chlorinated HDL is present in human lesion material,
binds to and is internalized by endothelial cells and impairs expression and activity of endothelial nitric
oxide synthase. The present study aimed at clarifying whether exposure of endothelial cells to pro-
inﬂammatory HOCl–HDL impacts on expression of heme oxygenase-1, a potential rescue pathway against
endothelial dysfunction. Our ﬁndings revealed that HDL modiﬁed by HOCl, added as reagent or generated
enzymatically, induced phosphorylation of p42/44 mitogen-activated protein kinase, expression of tran-
scription factor early growth response-1 (Egr-1) and enhanced expression of heme oxygenase-1 in
human endothelial cells. Upregulation of heme oxygenase-1 could be blocked by an inhibitor upstream
of p42/44 mitogen-activated protein kinase and/or knockdown of Egr-1 by RNA-interference. Electropho-
retic mobility shift assays demonstrated HOCl–HDL-mediated induction of the Egr-1 DNA binding activ-
ity. Immunocytochemical and immunoblotting experiments demonstrated HOCl–HDL-induced
translocation of Egr-1 to the nucleus. The present study demonstrates a novel compensatory pathway
against adverse effects of HOCl–HDL, providing cytoprotection in a number of pathological conditions
including cardiovascular disease.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Epidemiological studies have established an inverse correlation
between the risk for atherosclerosis, the plasma levels of
apolipoprotein A–I (apoA–I)1 and high-density lipoprotein (HDL)–
cholesterol. In line, pharmacological strategies show that raising
HDL–cholesterol prevents coronary heart disease [1]. Besides an
array of potential anti-inﬂammatory and anti-atherogenic activi-national Human Peroxidase
ecular Medicine, Institute of




l nitric oxide synthase; HDL,
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tein kinase; MPO, myeloper-
-NC-ND license.ties [2] the most important vasculoprotective function of apoA–I
and HDL is the role in ‘reverse cholesterol transport’ [3].
Accumulating evidence suggested that HDL and apoA–I become
dysfunctional in ‘reverse cholesterol transport’ after oxidative
modiﬁcation. The phagocytic enzyme myeloperoxidase (MPO), an
established cardiovascular risk factor [4], is considered a prime
modulator to form a pro-inﬂammatory and pro-atherogenic HDL
particle. MPO, abundantly present in neutrophils and monocytes
uses H2O2 and chloride ions to generate chlorinating oxidants, in
particular hypochlorous acid (HOCl), which play an important role
in killing microorganisms [5–7].
MPO is enzymatically active in human atheroma [8] and immu-
noreactivity for the enzyme is prominent in intimal mononuclear
cells in all regions of human atheroma [9]. Immunohistochemical
studies demonstrated that speciﬁc epitopes derived from HOCl
colocalized with apoA–I [10,11]. Findings that apoA–I represents
a selective target for MPO-catalyzed oxidation [12] support obser-
vations on functional impairment of modiﬁed HDL in vivo and
in vitro [13,14].
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topes with apoA–I on endothelial cells [10,14] suggested adverse
cellular effects of chlorinated HDL. We previously reported that
HOCl–HDL interacts with human umbilical venous endothelial
cells [15] thereby impairing their vasculoprotective function [16].
However, at sites of vascular inﬂammation endothelial cells may
exert adaptive responses against cell damage and denudation that
promote plaque erosion and thrombosis in vivo. Induction of induc-
ible heme oxygenase-1 (HO-1) by a broad spectrum of agents rep-
resents an important cytoprotective pathway to alleviate
endothelial dysfunction in response to inﬂammatory insults.
The cytoprotective effects of the stress-response protein HO-1
are reported to be due to its ability to degrade the pro-oxidative
heme to anti-oxidative bile pigments [17] and to generate carbon
monoxide that exhibits anti-proliferative, anti-inﬂammatory and
vasodilatory properties [18]. It was shown previously that HO-1
accumulation is accompanied by increased bilirubin levels in rab-
bit atherosclerotic lesions [19]. Induction of HO-1 expression re-
versed the progression of vulnerable plaques into more stable
lesions [20,21], whereas the lack of HO-1 led to an exacerbation
of plaque formation [22].
Nuclear factor E2-related factor 2 (Nrf2), a basic leucine zipper
transcription factor, binds to the cis-acting antioxidant response
element (ARE) of stress responsive genes including HO-1 [23]. It
was shown previously that oxidized low-density lipoprotein
promotes induction of HO-1 in human smooth muscle cells via
activation of protein kinase C, stress-activated protein kinase/
c-jun-NH2-terminal kinase, p38 and p42/44 mitogen-activated
protein kinases (MAPKs), and Nrf2 [24].
The zinc-ﬁnger transcription factor early growth response fac-
tor-1 (Egr-1) belongs to the family of immediate-early genes that
binds to GC-rich sequences in the promoter region of target genes
involved in the development of atherosclerosis [25–27]. Egr-1 is
highly expressed in human and mouse atherosclerotic lesions
[28] and is induced by modiﬁed low-density lipoprotein in human
monocytes [29]. Previous reports show that phosphorylation of
p42/44 MAPK leads to induction of Egr-1 expression [30,31] and
that transcriptional activation of HO-1 by Egr-1 is induced by sev-
eral triggers present in atherosclerotic vascular disease [32,33].
Oxidative stress causes enhanced endothelial cell injury in hu-
man and animal HO-1 deﬁciency [22,34]. As staining for MPO
and HOCl-modiﬁed epitopes was present within and around endo-
thelial cells in both human and animal lesions [35,36] where HO-1
is also highly expressed [37] the present study aimed at investigat-
ing signalling pathways leading to HO-1 expression in human
endothelial cells in response to HOCl–HDL.Materials and methods
Cell culture
Human EA.hy926 endothelial cells were grown in DMEM (Gibco
Invitrogen, Lofer, Austria) with 4.5 g/l glucose, 3.97 mM L-gluta-
mine and 1 mM sodium pyruvate supplemented with 10% (v:v)
FCS, 1% penicillin–streptomycin, 1 HAT supplement at 37 C in
a humidiﬁed atmosphere of 5% CO2.Isolation and modiﬁcation of human lipoproteins
Low-density lipoprotein (LDL, d = 1.035–1.065 g/ml) was iso-
lated from plasma of healthy, normolipidemic subjects by ultra-
centrifugation as described [38,39]. The protein of the ﬁnal LDL
preparation consisted of 96–98% apoB-100 as measured immuno-
chemically. HDL (subclass 3, density = 1.125–1.21 g/ml) was fur-
ther isolated by discontinuous density ultracentrifugation [10]and stored at 4 C until usage. The protein concentration was
determined by the Lowry method, using bovine serum albumin
(BSA) as a standard. Native LDL and HDL were desalted using PD-
10 desalting columns (GE Healthcare, Vienna, Austria) prior to
modiﬁcation. HOCl–LDL was prepared as described [40]. Brieﬂy,
one mg LDL protein per ml PBS (10 mM, pH 7.4) was incubated
with HOCl-solution (60 min, 4 C). For LDL incubated in between
0.2 and 1.6 mM ﬁnal HOCl concentration this resulted in an
oxidant:lipoprotein molar ratio in between 100:1 and 800:1. Mod-
iﬁcation of HDL by reagent HOCl was performed as described
[10,41]. Brieﬂy, 2.5 mg of HDL/ml of PBS (10 mM, pH 7.4) were
modiﬁed by the single addition of HOCl (see above). For HDL
(and BSA) incubated in between 0.2 and 1.6 mM ﬁnal HOCl concen-
tration this resulted in an oxidant:(lipo)protein molar ratio in be-
tween 25:1 and 200:1 [15,40]. Alternatively, HDL was modiﬁed
by the MPO–H2O2–chloride system [41] (approx. oxidant:lipopro-
tein molar ratio of 25:1). Brieﬂy, 1 mg of HDL/ml of PBS was mod-
iﬁed at pH 7.4 (37 C) by alternate additions of H2O2 [41] and MPO
(ﬁnal concentrations: 440 lM H2O2, 8 lg/ml MPO (Planta Natural
Products, Vienna, Austria)); in some experiments ascorbate was
added (ﬁnal concentration 14 lM; assuming a quantitative conver-
sion of H2O2, an oxidant:lipoprotein molar ratio up to 50:1 can be
expected). The modiﬁed (lipo)protein-preparations were passed
over a PD10 column to remove unreacted HOCl and used
immediately for cell culture experiments.
Cell culture experiments
Cells were seeded into respective cell culture dishes (Greiner
Bio-One, Frickenhausen, Germany) and grown until reaching con-
ﬂuence. The medium was changed to complete medium without
FCS and HAT and after 16 h incubation time, native or modiﬁed
HDL, LDL or BSA was directly added into the medium to start the
experiment. In some experiments, the cells were preincubated
for 30 min with the respective signal transduction inhibitors for
p42/44 MAPK kinase (PD98059, 25 lM) and for p38 MAPK
(SB203580, 10 lM) (Merck Biosciences, Darmstadt, Germany).
Experiments were terminated by aspiration of the medium and
washing the cells twice with cold PBS.
Western blot analysis
Cells were lysed on ice in 100 ll lysis buffer (50 mM Hepes,
150 mM NaCl, 1 mM EDTA, 10 mM Na4P2O7, 2 mM Na3VO4,
10 mM NaF, 1% (v:v) Triton X-100, 10% (v:v) glycerol and Complete
Mini protease inhibitor cocktail tablets (Roche Applied Science,
Vienna, Austria); pH 7.4) for 10 min. Cell lysates were scraped
and centrifuged to remove cell debris. Protein concentration was
determined according to Lowry. Three times reducing sample buf-
fer (8% (w:v) SDS, 18% (v:v) glycerine, 114 mM Tris (pH 6.8), 0.04%
(w:v) bromphenol-blue and 5% (v:v) mercaptoethanol) was added
to equal amounts (50–100 lg) of total cell lysates, and heated for
5 min at 95 C. Samples were subjected to electrophoresis on Nu-
PAGE 4–12% gradient Bis–Tris Gels (Invitrogen, Lofer, Austria)
and proteins were blotted to nitrocellulose. Membranes were
blocked with 5% (w:v) non-fat milk (30 min) and afterwards incu-
bated with the primary antibody at 4 C overnight. The following
primary antibodies were used: Mouse monoclonal b-actin (C4)
antibody, rabbit polyclonal lamin A/C (H-110) antibody, rabbit
polyclonal Egr-1 (C19) antibody and rabbit polyclonal Nrf2 (C-20)
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA);
mouse monoclonal phospho-p44/42 MAPK (Erk1/2) antibody and
rabbit polyclonal phospho-p38 MAPK antibody (Cell Signaling
Technology, Inc., Danvers, MA, USA); rabbit polyclonal HO-1
(Hsp32) antibody (Assay Designs, Inc., Ann Arbor, MI, USA). Perox-
idase-conjugated goat anti-rabbit IgG (Pierce Biotechnology, Inc.,
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(Rockland Immunochemicals, Inc., Gilbertsville, PA, USA) were
used as secondary antibodies and added at 25 C for 1.5 h. Immu-
noreactive bands were visualized by Super Signal West Pico
Chemiluminescent substrate.RNA isolation and real-time RT-PCR
Total RNA from endothelial cells was isolated using QIAshred-
der and RNeasy Mini Kit (QIAGEN, Hilden, Germany). One micro-
gram of RNA was subjected to DNaseI digestion and reverse
transcription (Invitrogen, Lofer, Austria) using random hexamer
primers (Applied Biosystems Inc., Foster City, CA, USA). Six nano-
grams of cDNA was used as template for each Real-time PCR. Gene
expression was determined by quantitative Real-time PCR using
the LightCycler 480 system (Roche Diagnostics, Vienna, Austria)
and the QIAGEN QuantiFast SYBR Green PCR Kit. QIAGEN Quanti-
Tect Primer Assays were used to determine gene expression of
Egr-1 (Hs_Egr1_2_SG), HO-1 (Hs_HMOX1_1_SG), and glyceralde-
hyde-3-phosphate dehydrogenase (Hs_GAPDH_2_SG), respec-
tively. For detection of Nrf2 gene expression the following primer
pair was used: forward 50-TAC TCC CAG GTT GCC CAC A-30 and re-
verse 50-CAT CTA CAA ACG GGA ATG TCT GC-30. Fold change in
gene expression levels of the target gene compared to the house-
keeping gene GAPDH was calculated by the 2DDCT method.Electrophoretic mobility shift assay (EMSA)
Cells were scraped in PBS, centrifuged at 500g (4 C, 3 min) and
nuclear proteins were isolated using NE-PER extraction reagents as
recommended by the manufacturer (Pierce Biotechnology, Inc.,
Rockford, IL, USA). Nuclear protein concentration was determinedFig. 1. Western blot analysis of native and modiﬁed HDL-induced MAPK activation in th
incubated with 100 lg/ml HDL or HOCl–HDL (oxidant:lipoprotein molar ratio 200:1) for
for 5 min. (E) Cells were preincubated for 30 min with 25 lM PD98059 or 10 lM SB20358
with 100 lg/ml native HDL or HDL modiﬁed by reagent HOCl (HOCl–HDL) or by the MPO
for 5 min. (A–F) Cells were lysed and equal amounts of proteins were subjected to Wester
used as a loading control. In all Western blots, lane 1 represents non-stimulated controls,
shown.using the BCA™ Protein Assay kit (Pierce Biotechnology, Inc.). Oli-
gonucleotide sequences of the Egr-1 consensus-binding site,
reported by Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA)
and synthesized by TibMolBiol (Berlin, Germany), were 50-GGA
TCC AGC GGG GGC GAG CGG GGG CGA-30 and 30-CCT AGG TCG
CCC CCG CTC GCC CCC GCT-50. Complementary oligonucleotides
were annealed and radioactive labelled using T4 Polynucleotide ki-
nase and [c-32P]ATP. After removal of unincorporated nucleotides
by Micro Bio-Spin-6 Chromatography Columns (Bio-Rad Laborato-
ries, Inc., Vienna, Austria), 5 lg of nuclear protein extracts were
incubated with 10 mM Tris pH 7.5, 50 mM NaCl, 1 mM DTT,
0.1 mM EDTA, 5% glycerol (v:v), 0.25 lg Poly[d(I-C)] and 5 lg
BSA at 25 C for 10 min. Labelled oligonucleotides were added to
each sample and EMSA binding reaction took place at 25 C for
20 min. A 20-fold molar excess of non-radiolabelled oligonucleo-
tides was added to the samples prior to the addition of labelled
probe for competition experiments. Glycerol was added to a ﬁnal
concentration of 20% (v:v) and samples were subjected to poly-
acrylamide gel electrophoresis (3.9% polyacrylamide gel; acrylam-
ide:bisacrylamide, 29:1) in 0.25% (v:v) Tris boric acid buffer at
25 C and 120 V for 3.5 h. The gel was dried under vacuum at
80 C for 1.5 h and then exposed to Hyperﬁlm™ MP (GE Health-
care, Vienna, Austria) for 12–24 h.Isolation of cytosolic and nuclear proteins
For translocation experiments, nuclear and cytosolic proteins
were isolated using a modiﬁcation of the method of Dignam
et al. [42,43]. Brieﬂy, cells were washed twice with cold PBS and
once with cold buffer A (10 mM Hepes pH 7.9, 1.5 mM MgCl2,
10 mM KCl, 1 mM DTT and Complete Mini protease inhibitor
cocktail tablets). Cells were lysed in buffer A including 0.1% (v:v)e absence or presence of MAPK inhibitors in endothelial cells. (A and C) Cells were
the indicated times or (B and D) with indicated concentrations of HDL or HOCl–HDL
0 prior to stimulation with 100 lg/ml HOCl–HDL for 5 min. (F) Cells were incubated
–H2O2-system in the absence (MPO–HDL) or presence of ascorbate (MPO–Asc–HDL)
n blot analysis for pp42/44 and pp38 MAPK. After stripping membranes, b-actin was
i.e. cells in the absence of lipoproteins. One representative experiment out of three is
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the supernatant, containing the cytosolic fraction, was stored at
70 C. The nuclear pellet was washed once in PBS, once in buffer
A and lysed in buffer C (20 mM Hepes pH 7.9, 0.42 M NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 1 mM DTT, 25% (v:v) glycerol and Complete
Mini protease inhibitor cocktail tablets) for 30 min on ice. Samples
were centrifuged at 21,000g (4 C, 20 min); the supernatant, con-
taining the nuclear fraction, was stored at 70 C.Immunoﬂuorescence and confocal laser scanning microscopy
Cells were cultured on Lab-Tek chamber slides (Thermo Fisher
Scientiﬁc, Rochester, NY, USA) and incubated in the absence (non-
stimulated) or presence of 100 lg/ml lipoprotein (HDL or
HOCl–HDL (200:1)) for 1 h. Afterwards the slides were washedwith
PBS, ﬁxed with 3.7% (v:v) formaldehyde for 20 min and re-hydrated
in PBS. After incubation with cold acetone for 3 min, slides were
again re-hydrated in PBS and blocked with DakoCytomation Anti-
body Diluent with Background Reducing Components (Dako, Inc.,
Carpinteria, CA, USA) for 45 min. Slides were then incubated with
a polyclonal rabbit anti-Egr-1 (C19) antibody (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA, diluted with antibody diluent
1:50) for 45 min, washed with PBS and incubated with a Cy-3-la-
belled goat anti-rabbit antibody (1:250, Jackson ImmunoResearch
Labs, Inc.,WestGrove, PA, USA) for 45 min. After rinsing in PBS, Hoe-
chst33258wasadded to the slides for15 min to counter stainnuclei.Fig. 2. Real-time RT-PCR and Western blot analysis for lipoprotein-induced Egr-1 and Nr
Cells were preincubated for 30 min with 25 lM PD98059 or 10 lM SB20358 prior to stim
were subjected to Real-time RT-PCR. Egr-1 mRNA expression level was normalized to
indicated times. (C) Cells were incubated with indicated concentrations of HOCl–HDL for
preincubated for 30 min with 25 lM PD98059 or 10 lM SB203580 prior to stimulation
proteins were subjected to Western blot analysis for Egr-1 and Nrf2. After stripping mem
with 25 lM PD98059 or 10 lM SB20358 prior to stimulation with 100 lg/ml lipoprotein
Nrf2 expression level was normalized to GAPDH. (B–E) Lane 1 represents non-stimu
experiment (performed in triplicate A, F) out of three is shown.Slides were washed with PBS and mounted with Moviol (Merck
Chemicals, Ltd., Nottingham,UK). Slideswere analyzedona confocal
laser-scanning microscope (Leica SP2, Leica Lasertechnik GmbH,
Heidelberg, Germany) using the 405 nm laser line for the excitation
of Hoechst and the 543 nm line for Cy-3. Detection settings were:
420–470 nm for Hoechst Stain and 590–670 nm for Cy-3.
siRNA transfection
Cells were cultured in six-well plates and grown until reaching
50% conﬂuence. siRNA transfection using Lipofectamine RNAiMAX
or Oligofectamine (Invitrogen, Lofer, Austria) and 50 or 100 nM of
siRNA, respectively, was performed according to the manufac-
turer’s suggestions. Cells were transfected either with Egr-1 siRNA
or with scrambled control siRNA (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) for 6 h. Medium was changed to complete
medium without FCS and HAT 30 h after transfection and 16 h
prior to incubation with 0.1 mg/ml native HDL or HOCl–HDL for
indicated time points.
Statistical analysis
Data are expressed as means ± SD for real-time PCR and densi-
tometric evaluations of immunoreactive bands. One-way ANOVA
including Bonferroni post-test was performed by using Prism 5
software (Graph pad Software, La Jolla, CA, USA). Means weref2 expression in endothelial cells in the absence or presence of MAPK inhibitors. (A)
ulation with 100 lg/ml lipoprotein for the indicated times. Equal amounts of RNA
GAPDH (⁄⁄⁄p < 0.001). (B) Cells were incubated with 100 lg/ml lipoprotein for the
1.5 h. (D) Cells were incubated with 100 lg/ml lipoprotein for 1.5 h. (E) Cells were
with 100 lg/ml HOCl–HDL for 1.5 h. (B–E) Cells were lysed and equal amounts of
branes, b-actin was used as a loading control. (F) Cells were preincubated for 30 min
for the indicated times. Equal amounts of RNA were subjected to real-time RT-PCR.
lated controls, i.e. cells in the absence of lipoproteins. (A–F) One representative
Fig. 4. HOCl–HDL-induced Egr-1 nuclear translocation in endothelial cells. (A and
B) Cells were incubated with 100 lg/ml lipoprotein for the indicated times. Cells
were lysed, nuclear and cytosolic extracts were isolated and equal amounts of
proteins were subjected to Western blot analysis for Egr-1 and Nrf2. After stripping
membranes, b-actin or lamin was used as cytosolic or nuclear loading control. (A)
Lanes 1 and 8 represents non-stimulated controls. (B) Lane 1 represents non-
20 C. Rossmann et al. / Archives of Biochemistry and Biophysics 509 (2011) 16–25considered as signiﬁcantly different at ⁄p < 0.05, ⁄⁄p < 0.01 and
⁄⁄⁄p < 0.001.
Results
HOCl–HDL-mediates activation of p42/44 and p38 MAPK
Native HDL has been reported to promote activation of p38
MAPK in human umbilical venous endothelial cells [44]. We here
show that native HDL is able to induce phosphorylation of p42/
44 and p38 MAPKs in a time- and concentration-dependent
manner in human EA.hy926 endothelial cells (Fig. 1A and B).
We further tested the capacity of chlorinated HDL to activate
these MAPKs. HOCl–HDL induced phosphorylation of p42/44 and
p38 MAPKs also in a time- and concentration-dependent manner
(Fig. 1C and D); maximum phosphorylation for both MAPKs was
observed between 5 and 10 min after stimulation (Fig. 1C) at a pro-
tein concentration of 100 lg protein (Fig. 1D, Supplement Fig. ID).
Phosphorylation of p42/44 by HOCl–HDL after 5 min was more
pronounced when compared to native HDL (Supplement Fig. IC).
Incubation of cells with PD98059 (an inhibitor for p42/44 MAPK ki-
nase) for 30 min prior to stimulation with HOCl–HDL completely
blocked phosphorylation of p42/44 MAPK (Fig. 1E). In contrast,
SB203580 did not impair immunoreactive pp38 MAPK but en-
hanced p42/44 MAPK phosphorylation (Supplement Fig. IE).
Next, modiﬁcation of HDL was performed enzymatically as
occurring under in vivo conditions. Modiﬁcation of HDL with HOCl
generated by the MPO–H2O2–chloride system in the absence or
presence of ascorbate (an enhancer of chlorination reaction of
MPO [45]) also led to pronounced phosphorylation of p42/44 and
p38 MAPKs as shown for HDL modiﬁed by reagent HOCl (Fig. 1F).Fig. 3. HOCl–HDL-induced Egr-1 DNA binding activity in endothelial cells. EMSA of
HOCl–HDL-induced Egr-1 DNA binding activity. Cells were stimulated with 100 lg/
ml HOCl–HDL for the indicated times, nuclear extracts were isolated and incubated
with radioactively labelled oligonucleotides of the Egr-1 consensus-binding site
([32P]-oligo-Egr-1). For competition experiments extracts were preincubated with a
20-fold molar excess of unlabeled oligonucleotides (oligo Egr-1) speciﬁc for Egr-1.
Lanes 1 and 2 represents non-stimulated controls, i.e. cells in the absence of
lipoproteins. One experiment out of three is shown.
stimulated controls. (A and B) One experiment out of three is shown.
Fig. 5. Immunocytochemistry of HOCl–HDL-induced nuclear translocation of Egr-1.
Cells were cultured in the absence (non-stimulated) or presence of 100 lg/ml
lipoprotein for 1 h. Cells were stained for Egr-1 (rabbit anti-Egr-1 antibody followed
by Cy-3-labelled goat anti-rabbit antibody, red) and Hoechst (blue). Control
experiments (antibody control) were performed by omitting the primary antibody.
Slides were then analyzed on a confocal laser-scanning microscope. The bar
represents 20 lm. One representative experiment out of three is shown. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
Fig. 6. Real-time RT-PCR and Western blot analysis of lipoprotein-induced HO-1 expression in endothelial cells. (A) Cells were stimulated with 100 lg/ml lipoprotein for the
indicated times. Equal amounts of RNA were subjected to Real-time RT-PCR. HO-1 expression was normalized to GAPDH (⁄⁄⁄p < 0.001). (B) Cells were incubated with 100 lg/
ml lipoprotein for the indicated times. (C) Cells were incubated with indicated concentrations of HOCl–HDL for 12 h. (D) Cells were incubated with 100 lg/ml lipoprotein for
12 h. (E) Cells were preincubated for 30 min with 25 lM PD98059 or 10 lM SB203580 prior to stimulation with 100 lg/ml HOCl–HDL for 12 h. Lane 4 represents non-
stimulated controls, i.e. cells in the absence of lipoproteins. (B–D) Lane 1 represents non-stimulated controls. (B–E) Cells were lysed and equal amounts of proteins were
subjected to Western blot analysis for HO-1. After stripping membranes, b-actin was used as a loading control. (A–E) One representative experiment (performed in triplicate
A) out of three is shown.
Fig. 7. Western blot analysis of (lipo)protein-induced HO-1 expression in endo-
thelial cells. (A) Cells were incubated with 100 lg protein/ml native and modiﬁed
lipoproteins (at indicated oxidant:lipoprotein molar ratio, 50:1 to 400:1) or (B)
100 lg protein/ml native and modiﬁed BSA (at indicated oxidant:protein molar
ratio, 25:1 to 200:1, FF = fatty-acid free) for 12 h. HOCl–HDL (200:1) was used as a
positive control. Cells were lysed and equal amounts of proteins were subjected to
Western blot analysis for HO-1. After stripping membranes, b-actin was used as a
loading control. Lane 1 represents non-stimulated controls (ns), i.e. cells in the
absence of lipoproteins. (A/B) One representative experiment out of three is shown.
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44 MAPK signalling
Next, we tested whether HOCl–HDL is able to induce known
transcriptional activators of the HO-1 gene, i.e. Egr-1 and Nrf2.
Fig. 2A shows time-dependent transcriptional activation of Egr-1in response to HOCl–HDL. HOCl–HDL rapidly activated transcrip-
tion of Egr-1 with maximum levels observed at 30 min. The
response to native HDL after 1 h was 50% lower compared to
HOCl–HDL. The p42/44 MAPK kinase inhibitor PD98059 com-
pletely prevented transcriptional activation of Egr-1 while the
p38 MAPK antagonist increased transcriptional activation of Egr-
1 in cells incubated with HOCl–HDL or HDL for 1 h (Fig. 2A). On
the protein level, HOCl–HDL potently induced expression of Egr-
1 in a time- and concentration-dependent manner (Fig. 2B and
C); maximum of Egr-1 induction was in between 1 and 1.5 h after
stimulation (Fig. 2B); native HDL only slightly induced Egr-1 on the
protein level (Fig. 2B; for densitometric evaluation see Supplement
Fig. IIB and C). As shown in Fig. 1F, HDL modiﬁed by HOCl gener-
ated via the MPO–H2O2–chloride system in the absence or pres-
ence of ascorbate had the same effect on Egr-1 protein
expression as HDL modiﬁed by reagent HOCl (Fig. 2D); the effect
of native HDL on Egr-1 mRNA and protein expression was less
pronounced (Fig. 2A, B and D).
To clarify whether MAPK activation is directly involved in Egr-1
protein expression, cells were preincubated with PD98059 or
SB203580 before stimulation with HOCl–HDL. In line with data
from Fig. 2A, the p42/44 MAPK kinase inhibitor completely blocked
expression of Egr-1 protein in response to HOCl–HDL (Fig. 2E).
Consistent with Egr-1 expression on mRNA level (Fig. 2A), preincu-
bation of cells with SB203580 prior to stimulation with HOCl–HDL
potentiated expression of Egr-1 also on the protein level (Fig. 2E).
In contrast to Egr-1, Nrf2 expression on mRNA (Fig. 2F) and protein
level (Fig. 2B–E) was unaffected by HOCl- or MPO-modiﬁed HDL
preparations.
To follow whether HOCl–HDL-mediated stimulation induces
Egr-1 DNA binding activity, nuclear proteins were subjected to
EMSA using a speciﬁc probe for Egr-1. Time-dependent stimulation
of cells with HOCl–HDL led to a maximum in Egr-1 binding after
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belled Egr-1 probe conﬁrmed the EMSA band as speciﬁc for Egr-1
(Fig. 3). This demonstrates that HOCl–HDL enhanced the binding
of Egr-1 to its consensus-binding site in the promoter region of tar-
get genes.
Time-course experiments of Egr-1 expression in the cytosolic
protein fraction revealed maximum expression in HOCl–HDL-trea-
ted cells approx. after 1 h (Fig. 4A). At this (Fig. 4B) and later time
points (1.5 h, Fig. 4A), pronounced Egr-1 expression became appar-
ent in the nuclear fraction. Egr-1 expression by native HDL was less
pronounced in the nuclear fraction compared to HOCl–HDL
(Fig. 4B). Time-course experiments demonstrated that HOCl–HDL
did not affect expression of Nrf2 in the cytosol nor promote nuclear
translocation of Nrf2 (Fig. 4A). Immunoﬂuorescence microscopy
conﬁrmed HOCl–HDL-induced nuclear translocation of Egr-1 in
endothelial cells (Fig. 5). In non-stimulated cells or cells incubated
with native HDL staining for Egr-1 was almost exclusively present
in the cytosol (Fig. 5).
HOCl–HDL-mediated induction of HO-1 via pp42/44 MAPK signalling
Next, we tested whether HOCl–HDL promotes induction of HO-
1. HOCl–HDL promoted high expression of HO-1 on mRNA levelFig. 8. Real-time RT-PCR andWestern blot analysis of HOCl–HDL-stimulated Egr-1 and H
transfected with 50 nM siRNA against Egr-1 or with scrambled control siRNA. Forty-eight
determine Egr-1 mRNA expression (A) and for 4 h to assess HO-1 mRNA expression
expression were normalized to GAPDH (⁄⁄⁄p < 0.001, ⁄⁄p < 0.01). (C and D) Cells were tran
48 h cells were stimulated with 100 lg/ml HOCl–HDL for 1.5 h to assess Egr-1 (C) and for
of proteins were subjected to Western blot analysis. b-Actin was used as a loading contro
(E) Western blot analysis of HOCl–HDL-induced nuclear translocation of Egr-1 in cells t
Egr-1 or with scrambled control siRNA and after 48 h cells were stimulated with 100 lg/
and equal amounts of proteins were subjected to Western blot analysis for Egr-1 and HO-
loading control. Lanes 1 and 5 represents non-stimulated controls. (A–E) One represent(maximum in between 4 and 8 h); native HDL had no effect on
HO-1 expression (Fig. 6A). Western blot experiments revealed that
HOCl–HDL induced expression of HO-1 in a time- and concentra-
tion-dependent manner (Fig. 6B and C) with a maximum HO-1
expression after 12 h (Fig. 6B). Induction of HO-1 was similar in
cells in the absence or presence of native HDL (Fig. 6B). HDL mod-
iﬁed by the MPO–H2O2–chloride system had a less pronounced ef-
fect on HO-1 expression (Fig. 6D). To directly address involvement
of MAPK activation in HO-1 expression, cells were preincubated
with respective MAPK (kinase) inhibitors. Only PD98059 impaired
expression of immunoreactive HO-1 (Fig. 6E). Although the p38
MAPK inhibitor SB203580 promoted activation of p42/44 MAPK
and expression of Egr-1, HO-1 expression was not affected.
Fig. 7A demonstrates that HO-1 expression increases with
increasing degree of HDL modiﬁcation. To reveal whether up-
regulation of HO-1 by HOCl–HDL is speciﬁc for HDL, the cells were
incubated with HOCl–LDL (Fig. 7A) or HOCl–BSA (Fig. 7B). Although
an increasing oxidant:(lipo)protein molar ratio of LDL and BSA
tended to increase HO-1 expression, HOCl–LDL and HOCl–BSA
were less effective inducers of HO-1 upregulation when compared
to HOCl–HDL. No difference in HO-1 expression was observed
when BSA or fatty acid-free BSA was used in cell culture
experiments.O-1 expression in endothelial cells treated with siRNA against Egr-1. (A/B) Cells were
hours after transfection, cells were stimulated with 100 lg/ml HOCl–HDL for 1 h to
(B). Equal amounts of RNA were subjected to Real-time RT-PCR. Egr-1 and HO-1
sfected with 50 nM siRNA against Egr-1 or with scrambled control siRNA and after
12 h to determine HO-1 (D) protein expression. Cells were lysed and equal amounts
l. Lane 1 represents non-stimulated controls, i.e. cells in the absence of lipoproteins.
reated with siRNA against Egr-1. Cells were transfected with 100 nM siRNA against
ml HOCl–HDL for 1 h. Cells were lysed, nuclear and cytosolic extracts were isolated
1. After stripping membranes, b-actin was used as a cytosolic and lamin as a nuclear
ative experiment (performed in triplicate A/B) out of three is shown.
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To reveal that Egr-1 is directly involved in HOCl–HDL-mediated
activation of HO-1, Egr-1 was silenced by RNA interference. Due to
the low basal Egr-1 mRNA and protein levels the silencing efﬁ-
ciency of RNA interference was analyzed in HOCl–HDL-treated
cells. Therefore, experiments revealed that under our experimental
conditions transfection of Egr-1 speciﬁc siRNA led to a reduced
silencing efﬁciency. Fig. 8A/B showed that a speciﬁc siRNA directed
against Egr-1 inhibits HOCl–HDL-mediated expression of Egr-1 and
HO-1 on mRNA level in between 40% and 50%. Western blot exper-
iments conﬁrmed knockdown of Egr-1 (1.5 h) and HO-1 protein
(12 h) up to 60% (Fig. 8C/D); the scrambled control siRNA had no
effect on HOCl–HDL-mediated induction of Egr-1 and HO-1.
Fig. 8E showed the presence of immunoreactive Egr-1 in the
cytosolic fraction. HOCl–HDL only slightly enhanced immunoreac-
tive Egr-1 in the cytosolic fraction compared to non-stimulated
cells (lanes 5 and 6); however, in parallel, HOCl–HDL increased
immunoreactive Egr-1 in the nucleus (lane 2). Silencing of Egr-1
resulted in a lower nuclear Egr-1 protein content as compared to
cells treated with scrambled control siRNA (Fig. 8E, lanes 3 and 4).
Expression of Nrf2 remained constant in the cytosol in the ab-
sence or presence of HOCl–HDL and was not detected in the nu-
cleus (Fig. 8E). These ﬁndings indicate that HOCl–HDL mediates
HO-1 expression via activation of transcription factor Egr-1.Discussion
Accumulating reports conﬁrmed that MPO-mediated loss of the
atheroprotective functional properties of HDL might provide a
novel mechanism linking inﬂammation and oxidative stress to
the pathogenesis of atherosclerosis [14,46,47]. HDL isolated from
human atheroma is modiﬁed by MPO-derived oxidants and even
acts as an in vivo carrier of MPO [13]. Most importantly, chloram-
ines, formed during HOCl-treatment of apoA–I lysine residues en-
hance binding of MPO to modiﬁed/chlorinated HDL [48] thus
favouring ampliﬁcation of the modiﬁcation cycle. In addition to de-
creased cholesterol acceptor activities, HDL modiﬁed by HOCl
(added as reagent or generated by the MPO–H2O2–chloride sys-
tem) is subject to efﬁcient uptake and degradation by macrophages
[41,49], an event leading to foam cell formation in vitro and in vivo.
Wang and co-workers [37] previously demonstrated high HO-1
expression in macrophages, foam cells and endothelial cells in hu-
man and animal atherosclerotic lesions. Furthermore, selective
overexpression of HO-1 decreased lesion size in apoE/ mice
[21,50]. Ishikawa and colleagues [51,52] showed that inducers of
HO-1 induce atheroprotective pathways e.g. diminished lesion size
in apoE/ mice and Watanabe heritable hyperlipidemic rabbits. In
line, double knockout mice deﬁcient in HO-1 and apoE develop lar-
ger and more advanced lesions than apoE/ littermates when fed
a hypercholesterolemic diet [22].
Induction of HO-1 expression functions as a protective feedback
mechanism to prevent endothelial cell dysfunction in response to
inﬂammatory assaults. Results of the present study indicate that
upregulation of HO-1 in response to pro-inﬂammatory chlorinated
HDL might represent a hitherto unrecognized protection pathway
in endothelial cells. We propose that the underlying signalling
machinery that leads to HO-1 transcription might function as a
ﬁrst line of defence against HOCl–HDL-mediated cell dysfunction.
Low concentrations of HOCl induce the apoptotic machinery in
endothelial cells [53] while high concentrations promote a signiﬁ-
cant rise in HO-1 via the Nrf2/ARE pathway to counteract mito-
chondrial dysfunction and cell death [54]. Nrf2 has recently been
reported to regulate the induction of HO-1 in response to various
forms of cellular stress, including hemodynamics and endoplasmicreticulum stress [50]. Moreover, ﬁbroblasts from Nrf2/ mice ex-
press reduced levels of HO-1 mRNA [55]. Results of the present
study identiﬁed an alternative pathway for HO-1 induction by
HOCl–HDL via intermediate activation of Egr-1. A striking observa-
tion was that the commonly used pharmacological inhibitor
SB203580 did not inhibit lipoprotein-induced p38 MAPK phos-
phorylation (Fig. 1E). However, this is in line with ﬁndings that
SB203580 does not block all p38 MAPK isoforms [56] but preferen-
tially exerts inhibition downstream of pp38 MAPK signalling [57].
Another observation was that the pyridinyl imidazole p38 MAPK
inhibitor SB203580 even enhanced p42/44 MAPK activation in
the presence of HOCl–HDL (Fig. 1E). This one-way communication
between p38 and p42/44 MAPKs has previously been addressed in
other cellular systems [58–61]. SB203580 inhibits p38 MAPK a-
isoform signalling leading to increased phosphorylation of p42/
44 MAPK [59,60]. As Egr-1 expression is p42/44 MAPK-dependent
under our experimental conditions, enhanced expression of Egr-1
on mRNA and protein levels in cells treated with HOCl–HDL and
SB203580 may be expected (Fig 2A/E). Recent ﬁndings revealed
that SB203580-mediated expression of Egr-1 in the absence or
presence of other agonists is completely blocked by addition of
p42/44 MAPK inhibitors [61]. Egr-1 transcription is activated by
different subgroups of MAPKs [30,31,62,63]. We here show that
activation of p42/44 by HOCl–HDL is an initial event in this cas-
cade. HOCl–HDL binds to scavenger receptor SR-BI [10,15] and
lipoprotein binding may promote phosphorylation of p42/44
MAPK [64]. Therefore, binding of HOCl–HDL to SR-BI might be an
initiating event in this cascade.
Egr-1 acts as transcriptional regulator of several genes impli-
cated in the pathogenesis of vascular disease [63]. Indeed, high-
level expression of Egr-1 and Egr-1 inducible genes have been
observed in human and murine lesion material [28]. Other data ob-
tained with ﬁbroblasts provide evidence that Egr-1 might directly
activate HO-1 [32,33]. We here show that treatment of endothelial
cells with chlorinated HDL involves activation of p42/44 MAPK,
subsequent expression and nuclear translocation of Egr-1 and di-
rect activation of HO-1. Multiple approaches were used to validate
this signalling pathway(s): ﬁrst, expression of Egr-1 and HO-1 in
response to HOCl–HDL was investigated on mRNA and protein le-
vel; second, a well characterized inhibitor revealed that Egr-1 and
HO-1-mediated activation is p42/44 MAPK dependent; third,
involvement of Egr-1 in HO-1 expression and its nuclear localiza-
tion was conﬁrmed by EMSA, immunoblotting, immunoﬂuores-
cence, and Egr-1 RNA interference, respectively. Most
importantly, Egr-1 activation was observed in response to HDL
modiﬁed by HOCl that was added as reagent or generated
enzymatically by the MPO–H2O2–chloride system; the HOCl:HDL
molar ratio used during the present study (25:1 to 50:1 for MPO-
modiﬁed HDL) most probably reﬂects physiological conditions.
Assuming a HOCl concentration up to 340 lM [65] under acute
inﬂammation and a HDL3 plasma concentration of 6–12 lM [41]
this would result in a HOCl:lipoprotein molar ratio under in vivo
conditions as mentioned above.
Treatment of human umbilical venous endothelial cells with
reagent HOCl or HOCl-modiﬁed lipoproteins leads to reduced
endothelial nitric oxide synthase (eNOS) dimer stability [66]
and reduced expression and activity of eNOS [16,67] apparently
due to eNOS delocalization from the plasma membrane. Heiss
and co-workers [68] demonstrated that eNOS downregulation in
endothelial cells parallels HO-1 induction with subsequent local
and transient heme deﬁciency. Most importantly, murine Egr-1
has recently been identiﬁed to promote transcriptional repression
of d-aminolevulinic acid synthase 1, the ﬁrst and rate-limiting
enzyme in heme biosynthesis [69]. Also taurine, when chlorinated
by the MPO–H2O2–chloride system, induces HO-1 expression and
inhibits NO synthesis [70]; however, this activation process
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HO-1 axis [71].
HO-1 is a cytoprotective enzyme and its induction commonly
occurs in the setting of increased cellular response to maintain
physiological haemostasis [50,56]. More recently it has been re-
ported that also in cultured smooth muscle cells, endoplasmic
reticulum stress increased HO-1 mRNA and protein via the ARE,
and this was associated with cell survival. However, these studies
mostly include activation of HO-1 via the Nrf2-axis [72]. HO-1 reg-
ulation responds to a large and broad spectrum of chemical stres-
ses, including agents that cause oxidative stress or diminish
oxygen and thiol-reactive agents. A number of in vitro studies have
shown that hydroperoxides, oxidized phospholipids, H2O2, and
HOCl, respectively, may induce HO-1 [50,54].
We now show that chlorinated HDL is able to promote expres-
sion of HO-1 via a selective signalling cascade involving p42/44
activation and nuclear translocation of Egr-1 (Figs. 3–8) although
the possibility of alternative activation pathways cannot be ex-
cluded. The ability of endothelial cells to respond adequately
against adverse effects of chlorinated HDL suggests a novel, Egr-
1- but not Nrf2-mediated compensatory pathway, providing
cytoprotection in a number of pathological conditions including
cardiovascular disease. Whether the lipid moiety of modiﬁed
HDL or chloramines are responsible for this effect is currently un-
der investigation.
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